Outpatient Antiviral Treatment for COVID-19 and Influenza
Early antiviral treatment can help reduce the duration of symptoms and certain complications in patients with risk factors for severe COVID-19 or influenza illness. Yet uptake remains low, and many patients who meet eligibility criteria for antivirals do not ultimately receive them. Results from this survey will help us understand why eligible patients are not receiving these therapeutics as well as resources that might help increase the uptake of antivirals to eligible patients.
We would like to better understand potential barriers to using antiviral therapeutics for COVID-19 and influenza.